Acta Med. 2008, 51: 215-221

A Comparison of the Neuroprotective Efficacy of Newly Developed Oximes (K156, K203) and Currently Available Oximes (Obidoxime, HI-6) in Cyclosarin-poisoned Rats

Jiří Kassaa, Jana Žďárová Karasováa, Sandra Tesařováb, Kamil Kučac, Kamil Musíleka

aUniversity of Defence, Faculty of Military Health Sciences, Department of Toxicology, Hradec Králové, Czech Republic
bThe 7th Field Hospital of the Czech Army, Hradec Králové, Czech Republic
cUniversity of Defence, Faculty of Military Health Sciences, Center of Advanced Studies, Hradec Králové, Czech Republic

Received August 1, 2008
Accepted December 1, 2008


1. Bajgar J. Organophosphate/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment. Adv Clin Chem 2004; 38:151–216. <>
2. Cassel G, Karlsson L, Waara L, Wee Ang K, Goransson-Nyberg A. Pharmacokinetics and effects of HI-6 in blood and brain of soman-intoxicated rats: a microdialysis study. Eur J Pharmacol 1997; 332:43–52. <>
3. Frantík E, Hornychová M. Clustering of neurobehavioral measures of toxicity. Homeostasis 1995; 36:19–25.
4. Hornychová M, Frantík E, Kubát J, Formánek J. Neurotoxicity profile of supermethrin, a new pyrethroid insecticide. Cent Eur J Publ Health 1995; 3:210– 8.
5. Kassa J. Review of oximes in the antidotal treatment of poisoning by organophosphorus nerve agents. J Toxicol Clin Toxicol 2002; 40:803–16. <>
6. Kassa J, Cabal J. A comparison of the efficacy of acetylcholinesterase reactivators against cyclohexyl methylphosphonofluoridate (GF agent) by in vitro and in vivo methods. Pharmacol Toxicol 1999; 84:41–5. <>
7. Kassa J, Karasová J, Musílek K, Kuča K. An evaluation of therapeutic and reactivating effects of newly developed oximes (K156, K203) and commonly used oximes (obidoxime, trimedoxime, HI-6) in tabun-poisoned rats and mice. Toxicology 2008; 243:311–6. <>
8. Kuča K, Cabal J, Jun D, Bajgar J, Hrabinová M. Potency of new structurally different oximes to reactivate cyclosarin-inhibited human brain acetylcholinesterase. J Enz Inhib Med Chem 2006; 21:663–6. <>
9. Kuča K, Cabal J, Jun D, et al. In vitro reactivation potency of some acetylcholinesterase reactivators against sarin- and cyclosarin-induced inhibitions. J Appl Toxicol 2005; 25:296–300. <>
10. Kuča K, Jun D, Musílek K. Structural requirements of acetylcholinesterase reactivators. Mini-Rev Med Chem 2006; 6:109–20. <>
11. Kuča K, Musílek K, Paar M, et al. Targeted synthesis of 1-(4-hydroxyiminomethylpyridinium)- 3-pyridinium propane dibromide – a new nerve agent reactivator. Molecules 2007; 12:1964–72. <> <PubMed>
12. Kuča J, Patočka J. Reactivation of cyclosarin-inhibited rat brain acetylcholinesterase by pyridinium-oximes. J Enz Inhib Med Chem 2004; 19:39–43. <>
13. Lotti M. Organophosphorus compounds. In: Spencer PS, Schaumburg HH (eds). Experimental and Clinical Neurotoxicology. New York: Oxford University Press 2000:898–925.
14. Lundy PM, Raved L, Amitai G. Development of the bisquaternary oxime HI-6 toward clinical use in the treatment of organophosphate nerve agent poisoning. Toxicol Rev 2006; 25:231–43. <>
15. Marrs TC. Organophosphate poisoning. Pharmacol Ther 1993; 58:51–66. <>
16. Marrs TC, Rice P, Vale JA. The role of oximes in the treatment of nerve agent poisoning in civilian casualties. Toxicol Rev 2006; 25:297–323. <>
17. McDonough JH Jr, Shih T-M Neuropharmacological modulation of nerve agent-induced seizure and neuropathology. Neurosci Biobehav Rev 1997; 21: 559–79. <>
18. Moser VC, Tilson H, McPhail RC, et al. The IPCS collaborative study on neurobehavioral screening methods: II. Protocol design and testing procedures. Neurotoxicology 1997; 18:929–38.
19. Musilek K, Holas O, Kuča K, et al. Synthesis of monooxime-monocarbamoyl bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against tabun- and paraoxon-inhibited acetylcholinesterase. J. Enz. Inhib. Med. Chem. 2008; 23:70–6. <>
20. Musílek K, Kuča K, Jun D, Doležal M. Progress in synthesis of new acetylcholinesterase reactivators during the period 1990–2004. Curr Org Chem 2007; 11:229–38. <>
21. Sakurada K, Matsubara K, Shimizu K, et al. Pralidoxime iodide (2-PAM) penetrates across the blood-brain barrier. Neurochem Res 2003; 28:1401–7. <>
22. Taylor P. Anticholinesterase agents. In: Hardman JG, Limbird LE (eds). The Pharmacological Basis of Therapeutics. New York: McGraw Hill 1996:161–76.
23. Wiener SW, Hoffman RS. Nerve agents: a comprehensive review. J Intensive Care Med 2004; 19:22–37. <>
24. Worek F, Eyer P, Szinicz L. Inhibition, reactivation and aging kinetics of cyclohexylphosphonofluoridate- inhibited human cholinesterases. Arch Toxicol 1998; 72:580–7. <>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal